Join Now

Category Archives: BioUtah News

Teiko.bio Launches with $11.6 Million Series A Financing to Advance High-Dimension Immune Profiling for Clinical Trials and Diagnostics Development

By Natalie Themm | Published December 20, 2021

Teiko.bio Launches with $11.6 Million Series A Financing to Advance High-Dimension Immune Profiling for Clinical Trials and Diagnostics Development.

| Tagged | Leave a comment

Rosivo closes seed-round paving the path for commercialization of patented cartilage implant technology

By Natalie Themm | Published December 20, 2021

Rosivo closes seed-round paving the path for commercialization of patented cartilage implant technology

| Tagged | Leave a comment

Pfizer to Acquire Arena Pharmaceuticals

By Denise Bell | Published December 17, 2021

Pfizer and Arena Pharmaceutical on Dec. 13 announced that the companies have entered into an agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.  Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per […]

Also posted in Industry News, Utah's Life Sciences Companies | | Leave a comment

IONIQ Sciences recognized as “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021″

By Natalie Themm | Published December 16, 2021

IONIQ Sciences, Inc. announced it has been awarded “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021” by Global 100.

| Tagged | Leave a comment

Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe

By Natalie Themm | Published December 16, 2021

Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022.

| Tagged | Leave a comment

Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND

By Natalie Themm | Published December 16, 2021

Clene presented data from the RESCUE-ALS Phase 2 study of CNM-Au8®, a catalytically active gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS).

| Tagged | Leave a comment

Pfizer to Acquire Arena Pharmaceuticals

By Natalie Themm | Published December 14, 2021

Arena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena.

| Tagged | Leave a comment

IONIQ’s breast cancer feasibility results published by IEEE

By admin | Published December 10, 2021

Salt Lake City, November 30, 2021 – In collaboration with two of our Scientific Advisors, IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is proud to announce the prestigious IEEE Access peer-reviewed journal has published a scientific manuscript on the life-saving potential of our ‘breakthrough’ bioimpedance technology in breast cancer. “Skin Electrical Resistance as a Diagnostic […]

| Leave a comment

Recursion loops in Roche, Genentech for multibillion-dollar AI drug discovery deal

By Natalie Themm | Published December 8, 2021

The artificial-intelligence-powered drug designer Recursion signed on to a wide-ranging collaboration with Roche and its Genentech division.

| Tagged | Leave a comment

ARUP Laboratories Earns Fourth Consecutive Utah Business Best Companies To Work For Award

By Natalie Themm | Published December 8, 2021

For the fourth consecutive year, Utah Business magazine has honored ARUP Laboratories with its Best Companies to Work For Award.

| Tagged | Leave a comment

Renalytix Reports Financial Results for First Quarter of Fiscal Year 2022

By Natalie Themm | Published December 7, 2021

Renalytix reported financial results for the quarter ended September 30, 2021.

| Tagged | Leave a comment

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology

By Natalie Themm | Published December 7, 2021

The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery

| Tagged | Leave a comment

A Special Thanks To Our Legacy and Platinum Elite Members